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Abstract: Zika virus (ZIKV) causes no-to-mild symptoms or severe neurological disorders.
To investigate the importance of viral and host genetic variations in determining ZIKV infection
outcomes, we created three full-length infectious cDNA clones as bacterial artificial chromosomes
for each of three spatiotemporally distinct and genetically divergent ZIKVs: MR-766 (Uganda,
1947), P6-740 (Malaysia, 1966), and PRVABC-59 (Puerto Rico, 2015). Using the three molecularly
cloned ZIKVs, together with 13 ZIKV region-specific polyclonal antibodies covering nearly the entire
viral protein-coding region, we made three conceptual advances: (i) We created a comprehensive
genome-wide portrait of ZIKV gene products and their related species, with several previously
undescribed gene products identified in the case of all three molecularly cloned ZIKVs. (ii) We found
that ZIKV has a broad cell tropism in vitro, being capable of establishing productive infection in 16 of
17 animal cell lines from 12 different species, although its growth kinetics varied depending on both
the specific virus strain and host cell line. More importantly, we identified one ZIKV-non-susceptible
bovine cell line that has a block in viral entry but fully supports the subsequent post-entry steps.
(iii) We showed that in mice, the three molecularly cloned ZIKVs differ in their neuropathogenicity,
depending on the particular combination of viral and host genetic backgrounds, as well as in the
presence or absence of type I/II interferon signaling. Overall, our findings demonstrate the impact
of viral and host genetic variations on the replication kinetics and neuropathogenicity of ZIKV and
provide multiple avenues for developing and testing medical countermeasures against ZIKV.
Keywords: Zika virus; flavivirus; infectious cDNA; replication; gene expression; neuropathogenesis;
viral genetic variation; host genetic variation
1. Introduction
Discovered in Uganda in 1947 in a febrile rhesus macaque [1], Zika virus (ZIKV) is a medically
important flavivirus [2] related to Japanese encephalitis (JEV), West Nile (WNV), dengue, and yellow
fever viruses [3]. Originally, it was confined within an equatorial belt running from Africa to Asia,
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with only about a dozen cases of human illness reported [4]. In 2007, however, it caused a major
outbreak of mild illness characterized by fever, rash, arthralgia, and conjunctivitis on the western
Pacific Island of Yap [5,6]. Since then, it has spread eastward across the Pacific Ocean, invading
French Polynesia and other Pacific Islands in 2013–2014 [7], reaching the Americas and Caribbean in
2015–2016 [8,9], and now threatening much of the world [10,11]. ZIKV is spread to humans mainly
through the bite of an infected Aedes species mosquito, e.g., Aedes aegypti or Aedes albopictus [12],
but it can also be transmitted from a mother to her child during pregnancy [13,14] or through sexual
contact [15,16]. Serious concerns have been raised over links to congenital neurological malformations
(e.g., microcephaly) and severe neurological complications (e.g., Guillain–Barré syndrome) [17,18].
Despite its continuous rapid spread and high pandemic potential, no vaccine or drug is available to
prevent or treat ZIKV infection.
ZIKV is an enveloped RNA virus with a nucleocapsid core comprising an ~11 kb plus-strand
RNA genome and multiple copies of the C protein; this core is surrounded by a lipid bilayer bearing
the anchored M and E proteins [19,20]. With regard to the molecular events that occur during ZIKV
infection, our current understanding of the molecular biology of closely related flaviviruses offers a
promising starting point for ZIKV research [21]. As the first step in flavivirus replication, the virion
binds to one or more cellular proteins on the surface of a host cell, and is then internalized via
clathrin-mediated endocytosis in a viral glycoprotein E-dependent manner [22–24]. Within endosomes,
the E glycoprotein undergoes low pH-induced conformational changes, followed by fusion of the viral
and host cell membranes [25–27]. In the cytoplasm, the viral genomic RNA functions initially as an
mRNA for the translation of a single long open reading frame (ORF) flanked by 5′ and 3′ non-coding
regions (NCRs) [28,29]; the resulting polyprotein is cleaved by viral and cellular proteases to generate
at least 10 mature proteins [30,31]: three structural (C, prM, and E) and seven nonstructural (NS1, 2A,
2B, 3, 4A, 4B, and 5). In JEV and WNV, ribosomal frameshifting is also used for the expression of
NS1’, a C-terminally extended form of NS1 [32–34]. A complex of the seven nonstructural proteins
directs viral RNA replication on the distinct virus-induced membranous compartments derived from
endoplasmic reticulum (ER) [35,36]. This replication process is catalyzed by two main viral components:
(i) NS3, with serine protease (and its cofactor, NS2B) and RNA helicase/NTPase/RTPase activity,
and (ii) NS5, with methyltransferase/guanylyltransferase and RNA-dependent RNA polymerase
activity [37]. Virus assembly begins with budding of the C proteins, complexed with a newly made viral
genomic RNA, into the ER lumen, and acquisition of the viral prM and E proteins. The prM-containing
immature virions travel through the secretory pathway; in the trans-Golgi network, a cellular furin-like
protease cleaves prM to yield the mature M protein, converting the immature particle to a mature
virion [38].
The clinical presentation of ZIKV infection is highly variable, ranging from no apparent symptoms
or mild self-limiting illness, to severe neurological disorders, such as microcephaly and Guillain–Barré
syndrome [10,17]. Fundamentally, the varied outcomes after infection with a pathogen depend on the
specific combination of pathogen and host genotypes [39]. On the virus side, a limited but significant
number of ZIKVs have been isolated from Africa, Asia, and the Americas during the past 70 years.
Recent phylogenetic analyses based on complete or near-complete viral genome sequences have
revealed that the spatiotemporally distinct ZIKV strains are grouped into two major genetic lineages,
African and Asian, with the 2015–2016 American epidemic strains originating from a common ancestor
of the Asian lineage [40–42]. Despite the continuous expansion of its genetic diversity, little is known
about the effect of viral genetic variation on the pathogenicity of ZIKV between the two lineages or
between different strains within a particular lineage. On the host side, much progress has recently been
made in developing murine models for ZIKV infection [43], including mice genetically engineered to
lack one or more components of the innate and adaptive immune systems that affect the development,
severity, and progression of ZIKV-induced disease [44–49]. However, the influence of host genetic
variation on susceptibility to ZIKV infection is largely unknown.
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To assess, experimentally, the impact of viral and host genetic variations on the outcome of ZIKV
infection, we have now generated (i) a unique panel of three functional bacterial artificial chromosomes
(BACs), each containing a full-length infectious cDNA for one of three genetically divergent ZIKV
strains, and (ii) an exclusive collection of 13 rabbit antisera capable of detecting almost all of the
ZIKV gene products and their related species. Using these functional genomics and immunologic
tools, together with various cell culture and mouse infection model systems, we show that the three
molecularly defined cDNA-derived ZIKVs have a similar viral protein expression profile, but display
biologically significant differences in in vitro growth properties and in vivo neuropathogenic potential
that depend on both viral and host genetic traits. Our study not only provides a powerful system for
the functional study of viral and host genetics in ZIKV replication and pathogenesis, but also offers a
valuable platform for the rational design of vaccines and therapeutics against ZIKV.
2. Materials and Methods
2.1. Cells and Viruses
Details of the 17 cell lines used in this study, including their growth medium and culture
conditions, are presented in Table 1. ZIKV MR-766 and P6-740 were obtained from the World Reference
Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch (Galveston, TX,
USA), and ZIKV PRVABC-59 was provided by the Centers for Disease Control and Prevention (Fort
Collins, CO, USA). In the case of all three ZIKVs, viral stocks were amplified once in Vero cells at a
multiplicity of infection (MOI) of 1.
Table 1. Cells used in this study.
Organism Cell Tissue Growth Medium a CultureCondition
Source (Catalog
Number) b
Human HEK Embryo, kidney MEM supplemented with 10% FBS, 2 mM L-glutamine, 0.1
mM NEAA, 1.0 mM SP, and PS
37oC, 5% CO2 ATCC
(CRL-1573)
Human Huh-7 Liver DMEM supplemented with 10% FBS, 0.1 mM NEAA, and
PS
37oC, 5% CO2 Charles M. Rice,
RU
Human SH-SY5Y Bone marrow A 1:1 mixture of MEM and Ham's F-12 nutrient medium
supplemented with 10% FBS, 0.1 mM NEAA, and PS
37oC, 5% CO2 ATCC
(CRL-2266)
Mouse MEF Embryo (C57BL/6),
fibroblast
DMEM supplemented with 10% FBS and PS 37oC, 5% CO2 ATCC
(SCRC-1008)
Mouse NIH/3T3 Embryo (NIH/Swiss),
fibroblast
DMEM supplemented with 10% FBS and PS 37oC, 5% CO2 ATCC
(CRL-1658)
Mouse NSC-34 Motor neuron-like
hybrid
DMEM (without SP) supplemented with 10% FBS and PS 37oC, 5% CO2 Cedarlane
(CLU140)
Monkey Vero Kidney α-MEM supplemented with 10% FBS and PS 37oC, 5% CO2 ATCC
(WHO-Vero)
Cow BT Turbinate DMEM (without SP) supplemented with 10% HS and PS 37oC, 5% CO2 ATCC
(CRL-1390)
Cow MDBK Kidney DMEM (without SP) supplemented with 10% HS and PS 37oC, 5% CO2 ATCC
(CCL-22)
Pig ST Testis α-MEM supplemented with 10% FBS and PS 37oC, 5% CO2 ATCC
(CRL-1746)
Sheep SFF-6 Fetus, fibroblast DMEM supplemented with 15% FBS and PS 37oC, 5% CO2 Irina A.
Polejaeva,
USU
Goat GFF-4 Fetus, fibroblast DMEM supplemented with 15% FBS and PS 37oC, 5% CO2 Irina A.
Polejaeva,
USU
Horse NBL-6 Skin, dermis EMEM supplemented with 10% FBS and PS 37oC, 5% CO2 ATCC
(CCL-57)
Dog MDCK Kidney MEM supplemented with EBSS, 10% FBS, 0.1 mM NEAA,
1.0 mM SP, and PS
37oC, 5% CO2 ATCC
(CCL-34)
Cat CRFK Kidney, cortex MEM supplemented with EBSS, 10% HS, 0.1 mM NEAA,
1.0 mM SP, and PS
37oC, 5% CO2 ATCC
(CCL-94)
Chicken CEF Embryo, fibroblast DMEM supplemented with 10% FBS and PS 37oC, 5% CO2 Sung-June Byun,
KNIAS
Mosquito C6/36 Larva (Aedes albopictus) MEM supplemented with EBSS, 10% FBS, 2 mM
L-glutamine, 0.1 mM NEAA, 1.0 mM SP, and PS
28oC, 5% CO2 ATCC
(CRL-1660)
a MEM, minimum essential medium; α-MEM, alpha minimum essential medium; DMEM, Dulbecco’s modified
eagle medium; EMEM, Eagle’s minimum essential medium; EBSS, Earle’s balanced salt solution; FBS, fetal bovine
serum; HS, horse serum; NEAA, nonessential amino acids; SP, sodium pyruvate; PS, penicillin-streptomycin.
b ATCC, American Type Culture Collection; RU, Rockefeller University; USU, Utah State University; KNIAS, Korea
National Institute of Animal Science.
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2.2. Sequence Alignment and Phylogenetic Analysis
Multiple sequence alignments were performed via ClustalX, and the phylogenetic tree was
constructed using MEGA and visualized via TreeView, as described [50]. Sequence identities between
aligned nucleotide and amino acid sequences were calculated using ClustalX.
2.3. Cloning
Standard molecular cloning techniques were used to create three full-length ZIKV cDNAs [51],
one each for MR-766, P6-740, and PRVABC-59 in the BAC plasmid pBeloBAC11 [52], designated
pBac/MR-766, pBac/P6-740, and pBac/PRVABC-59. The same cloning strategy was used to construct
all three full-length ZIKV cDNAs with the appropriate primer sets listed in Table 2. Essentially,
each full-length ZIKV cDNA flanked by the 5′ SP6 promoter and the 3′ PsrI/BarI restriction enzyme
site was created by joining five overlapping RT-PCR-generated cDNA fragments at four natural
restriction enzyme sites found in the viral genome (see below for detailed description of cloning
strategy). The cloned cDNAs were checked by restriction enzyme mapping and sequencing.
Table 2. Oligonucleotides used in this study.
Oligonucleotide Sequence a (5’ to 3’) Position b Direction
Z1RT GCTATTGGGTTCATGCCACAGATGGTCATCA 4531–4561 Reverse
Z1F tatgtttaaacAGTTGTTGATCTGTGTGAATCAGACTGCGA 1–30 Forward
Z1R tatggcgcgccAGGACCACCTTGAGTATGATCTCTCTCATG 4502–4531 Reverse
Z2RT ATTGTCATTGTGTCAATGTCAGTCACCACTA 7369–7399 Reverse
Z2F tatgtttaaacTCATTGTTTGGAGGAATGTCCTGGTTCTCA 2340–2369 Forward
Z2R tatggcgcgccTCAATGTCAGTCACCACTATTCCATCCACA 7358–7387 Reverse
Z3RT CTCCAGTTCAGGCCCCAGATTGAAGGGTGGGG 10603–10634 Reverse
Z3F tatgtttaaacGGAAGTCCCAGAGAGAGCCTGGAGCTCAGG 5627–5656 Forward
Z3R tatggcgcgccAAGGGTGGGGAAGGTCGCCACCTTCTTTTC 10583–10612 Reverse
S123-5sp1F ctaggatccttaattaacctgcagggggctgtta Forward
S123-5sp1R GATCAACAACTctatagtgtcccctaaatc 1–11 Reverse
S1-5sp2F ggacactatagAGTTGTTGATCTGTGTGAGTC 1–21 Forward
S1-5sp2R tatccgcggTAGCGCAAACCCGGGGTTCCTGAAT 860–884 Reverse
S1-3roF tatccgcggGGAAAAAGGGAGGACTTATGGTGTG 10191–10215 Forward
S1-3roR agggcggccgcgtatgtcgcgttccgtacgttctagAGAAACCATGGATTTCCCCACACC 10785–10807 Reverse
S23-5sp2F ggacactatagAGTTGTTGATCTGTGTGAATC 1–21 Forward
S23-5sp2R tatccgcggAACGCAAAGCCAGGGTTCCTGAATA 859–883 Reverse
S23-3roF tatccgcggGGGAAAAAGGGAAGACTTATGGTGT 10190–10214 Forward
S23-3roR agggcggccgcgtatgtcgccttccgtacgttctagAGACCCATGGATTTCCCCACACCG 10784–10807 Reverse
ZikaC-F tttgaattcGGTCTCATCAATAGATGGGGT 297–317 Forward
ZikaC-R tttctcgagctattaTCGTCTCTTCTTCTCCTTCCT 399–419 Reverse
ZikaM-F tttgaattcGCTGTGACGCTCCCCTCCCAT 753–773 Forward
ZikaM-R tttctcgagctattaGACTCTAATCAAGTGCTTTGT 828–848 Reverse
ZikaE-F tttgaattcCAGCACAGTGGGATGATCGTT 1416–1436 Forward
ZikaE-R tttctcgagctattaTCCTAGGCTTCCAAAACCCCC 1518–1538 Reverse
ZikaNS4A-F tttgaattcGGAGCGGCTTTTGGAGTGATG 6465–6485 Forward
ZikaNS4A-R tttctcgagctattaGGTCTCCGGCAATTGGGCCGC 6597–6617 Reverse
ZikaNS4B-F tttgaattcGTGACTGACATTGACACAATG 7374–7394 Forward
ZikaNS4B-R tttctcgagctattaGGAAGTTGCGGCTGTGATCAG 7506–7526 Reverse
ZikaF GAAGTGGAAGTCCCAGAGAG 5622–5641 Forward
ZikaR TGCTGAGCTGTATGACCCG 5757–5775 Reverse
ZikaProbe FAM-TGGAGCTCAGGCTTTGATTGGGTGAC-BHQ1 5646–5671 Forward
VeroF AGCGGGAAATCGTGCGTGAC 624–643 Forward
VeroR CAATGGTGATGACCTGGCCA 742–761 Reverse
VeroProbe HEX-CACGGCGGCTTCTAGCTCCTCCC-BHQ2 694–716 Forward
a ZIKV-specific sequences are indicated in uppercase normal letters, and Vero β-actin-specific sequences are shown
in uppercase italic letters. Other nonviral sequences are indicated in lowercase letters. Restriction enzyme sites
used for cDNA cloning are underlined. FAM, 6-Carboxyfluorescein; HEX, Hexachlorofluorescein; BHQ, Black hole
quencher. b Nucleotide position refers to the complete genome sequence of ZIKV PRVABC-59 (GenBank accession
number KX377337) or to the mRNA sequence of Vero β-actin (GenBank accession number AB004047).
(1) pBac/MR-766: The genomic RNA of ZIKV MR-766 (GenBank accession no. KX377335)
was used as a template for the synthesis of three overlapping cDNA fragments by RT-PCR with
the following primer sets: Frag-AMR-766 (4552 bp), Z1RT, and Z1F + Z1R; Frag-BMR-766 (5070 bp),
Z2RT, and Z2F + Z2R; and Frag-CMR-766 (5008 bp), Z3RT, and Z3F + Z3R. Each of the three cDNA
amplicons was subcloned into pBACSP6/JVFLx/XbaI [53], a derivative of the pBeloBAC11 plasmid,
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by ligating the 8381 bp PmeI-MluI fragment of pBACSP6/JVFLx/XbaI with the 4538, 5056, and 4994
bp PmeI-AscI fragments of the Frag-AMR-766, Frag-BMR-766, and Frag-CMR-766 amplicons, respectively.
This generated pBac/Frag-AMR-766 to -CMR-766. To introduce an SP6 promoter immediately upstream
of the first adenine residue of the viral genome, two cDNA fragments were first amplified individually
by (i) PCR of pBACSP6/JVFLx/XbaI with a pair of primers, S123-5sp1F + S123-5sp1R (S123-5sp1R
contains the antisense sequence of the SP6 promoter) and (ii) PCR of pRs/5′NCRMR-766 [54] with
another pair of primers, S1-5sp2F + S1-5sp2R. Subsequently, these two fragments were fused by a
second round of PCR with the outer forward and reverse primers S123-5sp1F + S1-5sp2R. The 1025
bp BamHI-SacII fragment of the fused PCR amplicons was ligated with the 2718 bp BamHI-SacII
fragment of pRs2, creating pRs/5′SPMR-766. To engineer a unique PsrI run-off site just downstream
of the last thymine residue of the viral genome, one cDNA fragment was amplified by PCR of
pRs/3′NCRMR-766 [54] with primers S1-3roF + S1-3roR (S1-3roR contains the antisense sequence of the
PsrI and NotI recognition sites in a row). The 649 bp SacII-NotI fragment of the resulting amplicons was
ligated with the 2667 bp SacII-NotI fragment of pRs2, creating pRs/3′ROMR-766. The full-length MR-766
cDNA clone pBac/MR-766 was then assembled by sequentially joining the 7456 bp PacI-NotI fragment
of pBACSP6/JVFLx/XbaI with the following five DNA fragments: (i) the 1004 bp PacI-XmaI fragment of
pRs/5’SPMR-766, (ii) the 3160 bp XmaI-XhoI fragment of pBac/Frag-AMR-766, (iii) the 3144 bp XhoI-NsiI
fragment of pBac/Frag-BMR-766, (iv) the 3041 bp NsiI-BamHI fragment of pBac/Frag-CMR-766, and (v)
the 619 bp BamHI-NotI fragment of pRs/3′ROMR-766.
(2) pBac/P6-740: The genomic RNA of ZIKV P6-740 (GenBank accession no. KX377336) was used
as a template for the synthesis of three overlapping cDNA fragments by RT-PCR with the following
primer sets: Frag-AP6-740 (4553 bp), Z1RT, and Z1F + Z1R; Frag-BP6-740 (5070 bp), Z2RT, and Z2F + Z2R;
and Frag-CP6-740 (5008 bp), Z3RT, and Z3F + Z3R. Each of the three cDNA amplicons was subcloned
into pBACSP6/JVFLx/XbaI, by ligating the 8381 bp PmeI-MluI fragment of pBACSP6/JVFLx/XbaI with
the 4539, 5056, and 4994 bp PmeI-AscI fragments of the Frag-AP6-740, Frag-BP6-740, and Frag-CP6-740
amplicons, respectively. This generated pBac/Frag-AP6-740 to -CP6-740. To introduce an SP6 promoter
immediately upstream of the first adenine residue of the viral genome, two cDNA fragments were
first amplified individually by (i) PCR of pBACSP6/JVFLx/XbaI with a pair of primers, S123-5sp1F
+ S123-5sp1R (S123-5sp1R contains the antisense sequence of the SP6 promoter) and (ii) PCR of
pRs/5′NCRP6-740 [54] with another pair of primers, S23-5sp2F + S23-5sp2R. Subsequently, these two
fragments were fused by a second round of PCR with the outer forward and reverse primers S123-5sp1F
+ S23-5sp2R. The 1025 bp BamHI-SacII fragment of the fused PCR amplicons was ligated with the
2718 bp BamHI-SacII fragment of pRs2, creating pRs/5′SPP6-740. To engineer a unique BarI run-off site
just downstream of the last thymine residue of the viral genome, one cDNA fragment was amplified
by PCR of pRs/3′NCRP6-740 [54] with primers S23-3roF + S23-3roR (S23-3roR contains the antisense
sequence of the BarI and NotI recognition sites in a row). The 649 bp SacII-NotI fragment of the resulting
amplicons was ligated with the 2667 bp SacII-NotI fragment of pRs2, creating pRs/3′ROP6-740. The
full-length P6-740 cDNA clone pBac/P6-740 was then assembled by sequentially joining the 7456
bp PacI-NotI fragment of pBACSP6/JVFLx/XbaI with the following five DNA fragments: (i) the 187
bp PacI-NheI fragment of pRs/5′SPP6-740, (ii) the 2930 bp NheI-SpeI fragment of pBac/Frag-AP6-740,
(iii) the 3359 bp SpeI-NgoMIV fragment of pBac/Frag-BP6-740, (iv) the 4059 bp NgoMIV-StuI fragment
of pBac/Frag-CP6-740, and (v) the 433 bp StuI-NotI fragment of pRs/3′ROP6-740.
(3) pBac/PRVABC-59: The genomic RNA of ZIKV PRVABC-59 (GenBank accession no. KX377337)
was used as a template for the synthesis of three overlapping cDNA fragments by RT-PCR with
the following primer sets: Frag-APRVABC-59 (4553 bp), Z1RT, and Z1F + Z1R; Frag-BPRVABC-59
(5070 bp), Z2RT, and Z2F + Z2R; and Frag-CPRVABC-59 (5008 bp), Z3RT, and Z3F + Z3R. Each of
the three cDNA amplicons was subcloned into pBACSP6/JVFLx/XbaI, by ligating the 8381 bp
PmeI-MluI fragment of pBACSP6/JVFLx/XbaI with the 4539, 5056, and 4994 bp PmeI-AscI fragments
of the Frag-APRVABC-59, Frag-BPRVABC-59, and Frag-CPRVABC-59 amplicons, respectively. This generated
pBac/Frag-APRVABC-59 to -CPRVABC-59. To introduce an SP6 promoter immediately upstream of the first
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adenine residue of the viral genome, two cDNA fragments were first amplified individually by (i) PCR
of pBACSP6/JVFLx/XbaI with a pair of primers, S123-5sp1F + S123-5sp1R (S123-5sp1R contains the
antisense sequence of the SP6 promoter) and (ii) PCR of pRs/5′NCRPRVABC-59 [54] with another pair of
primers, S23-5sp2F + S23-5sp2R. Subsequently, these two fragments were fused by a second round of
PCR with the outer forward and reverse primers S123-5sp1F + S23-5sp2R. The 1025 bp BamHI-SacII
fragment of the fused PCR amplicons was ligated with the 2718 bp BamHI-SacII fragment of pRs2,
creating pRs/5′SPPRVABC-59. To engineer a unique BarI run-off site just downstream of the last thymine
residue of the viral genome, one cDNA fragment was amplified by PCR of pRs/3′NCRPRVABC-59 [54]
with primers S23-3roF + S23-3roR (S23-3roR contains the antisense sequence of the BarI and NotI
recognition sites in a row). The 649 bp SacII-NotI fragment of the resulting amplicons was ligated with
the 2667 bp SacII-NotI fragment of pRs2, creating pRs/3′ROPRVABC-59. The full-length PRVABC-59
cDNA clone pBac/PRVABC-59 was then assembled by sequentially joining the 7456 bp PacI-NotI
fragment of pBACSP6/JVFLx/XbaI with the following five DNA fragments: (i) the 187 bp PacI-NheI
fragment of pRs/5′SPPRVABC-59, (ii) the 4426 bp NheI-EcoNI fragment of pBac/Frag-APRVABC-59, (iii) the
2114 bp EcoNI-SacII fragment of pBac/Frag-BPRVABC-59, (iv) the 3808 bp SacII-StuI fragment of
pBac/Frag-CPRVABC-59, and (v) the 433 bp StuI-NotI fragment of pRs/3′ROPRVABC-59.
A total of five bacterial expression plasmids were constructed, each of which was used to express a
32 to 51 aa non-hydrophobic region of the ZIKV polyprotein as a glutathione S-transferase (GST) fusion
protein. In all cases, a defined region of the ZIKV ORF was amplified by PCR using pBac/PRVABC-59
as a template and the appropriate pair of primers listed in Table 2: (i) Frag-zC (147 bp), ZikaC-F
+ ZikaC-R; (ii) Frag-zM (120 bp), ZikaM-F + ZikaM-R; (iii) Frag-zE (147 bp), ZikaE-F + ZikaE-R;
(iv) Frag-zNS4A (177 bp), ZikaNS4A-F + ZikaNS4A-R; and (v) Frag-zNS4B (177 bp), ZikaNS4B-F +
ZikaNS4B-R. Each of the resulting amplicons was cloned into pGex-4T-1 (GE Healthcare, Piscataway,
NJ, USA) by ligating the 4954 bp EcoRI-XhoI fragment of the pGex-4T-1 vector with 135, 108, 135, 165,
and 165 bp EcoRI-XhoI fragments of the Frag-zC, -zM, -zE, -zNS4A, and -zNS4B amplicons, respectively.
This created pGex-zC, -zM, -zE, -zNS4A, and -zNS4B.
2.4. Transcription and Transfection
Infectious transcripts were synthesized from PsrI/BarI-linearized BAC plasmid DNA with SP6
RNA polymerase as described [53] in reactions containing m7GpppA (New England Biolabs, Ipswich,
MA, USA). RNA integrity was examined by agarose gel electrophoresis. RNA was transfected into
Vero cells by electroporation using the BTX ECM 830 electroporator with a 2-mm-gap cuvette under
optimized conditions (980 V, 99 µs pulse length, and 3 pulses); RNA infectivity was quantified by
infectious center assay [55,56]. The infectious centers of plaques/foci formed on the monolayer of Vero
cells were visualized at 5 days after transfection either nonspecifically by counterstaining of uninfected
cells with crystal violet [55] or specifically by immunostaining of ZIKV-infected cells with rabbit
anti-ZIKV NS1 (α-ZNS1) antiserum and horseradish peroxidase-conjugated goat α-rabbit IgG (Jackson
ImmunoResearch, West Grove, PA, USA), followed by developing with 3,3′-diaminobenzidine [56].
2.5. Growth Kinetics and Cytopathogenicity
Viral growth kinetics and cytopathogenicity were analyzed in 17 animal cell lines from 12 different
species. In each case, naïve cells were seeded into 35 mm culture dishes at a density of 3× 105 cells/dish
for 12 h, and then mock-infected or infected with viruses at an MOI of 1 for 1 h at 37 ◦C. Following
incubation, cell monolayers were washed and incubated with complete medium. At 6, 12, 18, 24, 36,
48, 60, 72, and 96 h post-infection (hpi), ZIKV-infected cells were examined morphologically under a
light-inverted microscope (Primo Vert, Carl Zeiss, Jena, Germany) to assess the degree of ZIKV-induced
cytopathic effect (CPE) as compared to mock-infected cells, and culture supernatants were collected to
evaluate the levels of virus production by plaque assays on Vero cells, as described [57]. The infectious
centers of plaques were visualized at 5 days after infection by counterstaining of uninfected cells with
crystal violet [55].
Viruses 2018, 10, 422 7 of 28
2.6. Real-Time RT-PCR
ZIKV RNA levels in infected Vero cells were quantified as described [57] by real-time RT-PCR
with the primer pairs and fluorogenic probes listed in Table 2: the ZikaF + ZikaR and ZikaProbe
specific for the ZIKV NS3-coding region that has the identical sequences in all three ZIKVs, and the
VeroF + VeroR and VeroProbe specific for the Vero β-actin coding region. Each ZIKV RNA level was
normalized to the corresponding β-actin mRNA level as an internal control.
2.7. Immunoblotting, Confocal Microscopy, and Flow Cytometry
Individual ZIKV proteins were identified by immunoblotting [31] using each of our six previously
characterized JEV region-specific rabbit antisera that cross-react with their ZIKV counterparts, or seven
newly generated ZIKV region-specific rabbit antisera. The rabbit antibody was detected using alkaline
phosphatase (AP)-conjugated goat α-rabbit IgG (Jackson ImmunoResearch, West Grove, PA, USA),
and the AP enzyme was visualized using colorimetric detection with 5-bromo-4-chloro-3-indolyl
phosphate and nitro blue tetrazolium (Sigma, St. Louis, MO, USA). ZIKV E proteins were visualized by
confocal microscopy [57] with rabbit α-ZE antiserum, followed by secondary labeling with fluorescein
isothiocyanate-conjugated goat α-rabbit IgG (Jackson ImmunoResearch). ZIKV NS4A proteins were
detected by flow cytometry [58] with rabbit α-ZNS4A antiserum, followed by secondary labeling with
Alexa 488-conjugated goat α-rabbit IgG (Invitrogen, Carlsbad, CA, USA).
2.8. Mouse Studies
ZIKV neuropathogenicity was examined in male and female mice of four strains: CD-1 (1, 2,
and 4 weeks, Charles River, Wilmington, MA, USA), C57BL/6J (4 weeks, the Jackson Laboratory, Bar
Harbor, ME, USA), A129 (4 weeks, bred in-house), and AG129 (4 weeks, bred in-house). Groups of
mice were inoculated via the intramuscular (im, 50 µL) or intracerebral (ic, 20 µL) route with 10-fold
serial dilutions of virus stock in α-minimal essential medium and monitored for any ZIKV-induced
clinical signs, weight loss, or death daily for 20 days. The im and ic lethal dose 50% (LD50) values for
each virus were calculated from the respective dose-dependent survival curves of the infected mice, as
described [57].
2.9. Ethics Statement
All mouse studies were conducted in strict accordance with the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health, United States of America. The animal protocol
was approved by the Institutional Animal Care and Use Committee (IACUC) of Utah State University
(approved IACUC protocol #2505, 30/03/2016). Discomfort, distress, pain, and injury were minimized
as much as possible through limited handling and euthanization of mice when they were moribund.
3. Results
3.1. Characterization of Three Spatiotemporally Distinct and Genetically Divergent ZIKV Strains
As an initial step in examining the genetic diversity of ZIKV and its biological significance for viral
replication and pathogenesis, we selected three historically important strains of distinct geographical
and temporal origins: (i) MR-766, the first ZIKV identified from the blood of a rhesus macaque
monkey in Uganda in 1947 [1]; (ii) P6-740, the first non-African strain, isolated from a pool of A.
aegypti mosquitoes in Malaysia in 1966 [59]; and (iii) PRVABC-59, the recent American strain recovered
from the blood of a human patient in Puerto Rico in 2015 [60]. To compare the genome sequence and
composition of these three ZIKVs, we determined the consensus nucleotide sequence for each of their
full-length genomic RNAs [54]. In all three strains of ZIKV, we found that the genomic RNA is 10,807
nt long, with a single ORF of 10,272 nt flanked by a 106 or 107 nt 5′NCR and a 428 or 429 nt 3′NCR
(Figure 1A). Also, the three genomic RNAs all begin with the dinucleotide 5′-AG and end with the
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dinucleotide CU-3′, both of which are conserved among all mosquito- and tick-borne flaviviruses.
However, pairwise sequence comparisons of the three complete genomes showed a considerable
degree of genetic diversity, with a range in sequence identity of 89.1–95.6% at the nucleotide level
and 96.8–98.8% at the amino acid level over the 3423 aa polyprotein encoded by the single ORF of the
genomic RNA (Figure 1B).
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Figure 1. A spectrum of ZIKV genetic div is represented by three historically important and
spatiotemporally distinct strains: MR-766, P -740, and PRVABC-59. The consensus n cleotide sequence
for each of their full-length genomic RNAs was determined by sequencing three overlapping uncloned
cDNA amplicons collectively representing the entire genomic RNA, except for the 5′ and 3′ termini,
which were subsequently defined by performing both 5′- and 3′-rapid amplification of cDNA ends
(RACE); each of these RACEs was followed by cDNA cloning and sequencing of ~20 randomly
picked clones. (A) Genomic organization of the three ZIKV strains; (B) Pairwise comparison of the
complete nucleotide (nt) and deduced amino acid (aa) sequences of the three ZIKV genomes; (C)
Phylogenetic tree based on the nucleotide sequence of 29 ZIKV genomes, including the 15 complete
(MR-766, green; P6-740, orange; PRVABC-59, red; and 12 others, black) and 14 near-complete (gray)
genomes, with Japanese encephalitis virus (JEV) K87P39 included as an outgroup. Bootstrap values
from 1000 replicates are shown at each node of the tree. The scale bar represents the number of
nucleotide substitutions per site. The strain name is followed by a description in parenthesis of the
country, year, and host of isolation and the GenBank accession numbers. Note that MR-766 has been
fully sequenced in this study and by three other groups (designated MR-766/CDC, MR-766/NIID,
and MR-766/USAMRIID).
To examine the genetic relationship between the three spatiotemporally distinct ZIKVs and their
associations with other strains, we performed a multiple sequence alignment for phylogenetic analysis
using the nucleotide sequence of all 29 ZIKV genomes (15 complete, 14 near-complete) in GenBank at
the time of analysis (June 2016), including our complete nucleotide sequence of the genomes of MR-766,
P6-740, and PRVABC-59. Construction of a genome-based rooted phylogenetic tree using JEV K87P39
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as an outgroup revealed two distinct phylogenetic groups (Figure 1C), in agreement with previous
ORF-based phylogenetic studies that classified 10–40 ZIKV isolates into two major genetic lineages,
African and Asian [40–42]. The African lineage branches into two clusters, one including four different
versions of the Ugandan MR-766 strain (1947) that are not identical in genome sequence, mainly
because of a variation in the passage history of the virus, and the other including the three Senegalese
isolates 41671-DAK, 41525-DAK, and 41662-DAK, all isolated in 1984. On the other hand, the Asian
lineage contains a single cluster of the Malaysian P6-740 (1966), Cambodian FSS13025 (2010), Philippine
CPC-0740 (2012), and Thai SV0127-14 (2014) strains, as well as 18 other isolates collected during the
2015–2016 American epidemic, including the Puerto Rican PRVABC-59 strain (2015). Notably, the four
pre-epidemic Asian strains (P6-740, FSS13025, CPC-0740, and SV0127-14) are closely related to the
2015–2016 American epidemic strains, but each forms a single minor branch. Overall, our data indicate
that MR-766 belongs to the African lineage, whereas both P6-740 and PRVABC-59 belong to the Asian
lineage, with PRVABC-59 being derived from an ancestor of the Asian lineage.
3.2. Development of Genetically Stable Full-Length Infectious cDNA Clones for the Three ZIKV Strains
We constructed three full-length infectious ZIKV cDNAs for the MR-766, P6-740, and PRVABC-59
strains, each capable of serving as a template for the rescue of molecularly cloned ZIKVs (Figure 2).
In each strain, five overlapping cDNA fragments representing the 10,807 nt genomic RNA were
sequentially assembled into a full-length cDNA in the single-copy BAC vector pBeloBAC11, in order
to ensure the stable maintenance of the cloned cDNA during propagation in Escherichia coli,
with an SP6 promoter sequence positioned immediately upstream of the viral 5′-end and a unique
restriction endonuclease recognition site (PsrI for MR-766, BarI for P6-740 and PRVABC-59) placed
just downstream of the viral 3′-end. Both the SP6 promoter and the unique restriction site were
engineered so that in vitro run-off transcription could be used to produce m7G-capped synthetic RNAs
bearing authentic 5′ and 3′ ends of the viral genomic RNA. Using this BAC-based cloning strategy,
we thus created a panel of three full-length ZIKV cDNAs, designated pBac/MR-766, pBac/P6-740,
and pBac/PRVABC-59 (Figure 2A).
To evaluate the functionality of the three full-length ZIKV BACs, we determined the viability of
the synthetic RNAs transcribed in vitro from each BAC by measuring their specific infectivity after
RNA transfection into a ZIKV-susceptible African green monkey kidney (Vero) cell line. To prepare a
DNA template for in vitro run-off transcription, the three full-length ZIKV BACs were first linearized
by digestion with PsrI (for pBac/MR-766) or BarI (for pBac/P6-740 and pBac/PRVABC-59). Each was
then used as a template for a run-off transcription reaction using SP6 RNA polymerase in the
presence of the m7GpppA cap structure analog. After removal of the DNA template by DNase I
digestion, we transfected Vero cells with the RNA transcripts, quantifying their infectivity as the
number of plaque-forming units (PFU) per µg of transfected RNA. In all three BACs, the RNA
transcripts invariably had a high infectivity of 8.1–8.6 × 105 PFU/µg and were capable of producing
a high-titer stock of infectious ZIKVs in culture medium that reached 1.3–5.0 × 106 PFU/mL at 36 h
after transfection (Figure 2B). Each of the three recombinant BAC-derived ZIKVs (designated by
the prefix “r”) formed a homogeneous population of plaques that differed from the others in size,
with mean diameters of 5.7 (rMR-766), 1.6 (rP6-740), and 5.2 (rPRVABC-59) mm (Figure 2C). We also
demonstrated that using pBac/P6-740, the infectivity of its RNA transcripts was decreased by ~4 logs
to a barely detectable level (55–105 PFU/µg), with a single C9804→U substitution (an unintended
mutation introduced during the overlapping cDNA synthesis by RT-PCR) replacing a His with Tyr
at position 713 of the viral NS5 protein (Figure S1A,B). On the crystal structure of ZIKV NS5 [61,62],
the His-713 residue is located within the conserved structural motif E region near the priming loop in
the RNA-dependent RNA polymerase domain (Figure S1C), suggesting a critical role for His-713 in
the polymerase function of ZIKV NS5.
Next, we examined the genetic stability of the three full-length ZIKV BACs that are important
for reliable and efficient recovery of infectious viruses from the cloned cDNAs. A single colony of
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E. coli DH10B carrying each of the three full-length ZIKV BACs was grown in liquid medium and
serially passaged for 4 days by diluting it 106-fold daily, such that each passage represented ~20
generations, as we described previously [53]. In all three cases, we found no differences in specific
infectivity of the RNA transcripts made from the BAC plasmids even after 80 generations, indicating
that the three full-length ZIKV BACs are stable during propagation in bacteria (Figure S2). In sum,
we have established genetically stable BAC-based reverse genetics platforms for the recovery of three
molecularly cloned, genetically distinct ZIKVs.
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Figure 2. A trio of functional ZIKV cDNAs was created for the rescue of three molecularly cloned
genetically divergent strains: rMR-766, rP6-740, and rPRVABC-59. (A) Construction of three full-length
ZIKV cDNAs as BACs for MR-766, P6-740, and PRVABC-59. In all three cases, each genomic RNA
(top panel) was first subcloned into five overlapping cDNAs (middle panel), which were then joined
at four shared restriction sites as indicated to asse ble its full-length cDNA without introducing
any point mutations for cloning (bottom panel). Presented bel w th three full-length cDNAs are
the sequences corresponding o the 5′ and 3′ termini conserved in all three ZIKVs (black lowercase),
an SP6 promoter placed just upstream of the viral genome (magenta uppercase), and a run-off site
positioned immediately downstream of the viral genome (PsrI or BarI, blue uppercase). Marked
below the sequences are the transcription start (white arrowhead) and run-off (black arrowhead)
sites; (B) Functionality of the three full-length ZIKV cDNAs. After linearization with PsrI or BarI, as
appropriate, each full-length cDNA was used as a template for in vitro transcription with SP6 RNA
polymerase in the presence of the dinucleotide c p analog m7GpppA. Capped RN transcripts were
transfected int Vero c lls to determine the number of infectious centers (plaques) counterstained
with crystal violet at 5 days after transfection (RNA infectivity). At 36 h post-transfection, culture
supernatants from RNA-transfected cells were harvested to estimate the level of virus production by
plaque assays on Vero cells (Virus yield). Means and standard deviations from three independent
experiments are shown; (C) Plaque morphology. The average plaque sizes were estimated by measuring
20 representative plaques.
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3.3. Differential Replication Kinetics and Cytopathogenicity among Three Molecularly Cloned ZIKVs in
Human, Mosquito, and Animal Cell Lines
To test whether the genetic variation in ZIKV can have differential effects on its replication kinetics
and cytopathogenicity, we infected monkey kidney-derived Vero cells at an MOI of 1, then examined
the replicative and cytopathic properties of the three cloned cDNA-derived ZIKVs (rMR-766, rP6-740,
and rPRVABC-59) as compared to those of the uncloned parental ZIKVs (MR-766, P6-740, and
PRVABC-59) used for cDNA construction. In all three strains, we saw no noticeable differences
between the cloned and uncloned viruses in the accumulation of viral genomic RNA over the first
24 hpi (Figure 3A), paralleling not only the kinetics of viral growth and CPE development over the
first 3 days post-infection (Figure 3B) but also the average sizes of the α-ZNS1 antibody-reactive
foci immunostained at 5 days post-infection (Figure 3C). However, we did observe clear differences
between the three strains, regardless of whether they were cloned or uncloned viruses, with respect to
their replication kinetics and cytopathogenicity (Figure 3A–C). Our specific findings are as follows:
(i) rMR-766/MR-766 displayed the fastest rate of RNA replication, induced complete lysis of the
infected cells by 36 hpi, achieved the highest virus titer of 2.0–3.3 × 107 PFU/mL at 36–48 hpi, and
formed the largest foci of 6.3 mm diameter. (ii) rP6-740/P6-740 had the slowest rate of RNA replication,
did not cause complete CPE until 72 hpi, reached its maximal virus titer of 1.1–1.2 × 107 PFU/mL at
60–72 hpi, and generated the smallest foci of 2.4 mm diameter. (iii) rPRVABC-59/PRVABC-59 had a rate
of RNA replication slightly slower than rMR-766/MR-766 but much faster than that of rP6-740/P6-740;
it caused complete CPE by 48 hpi, with a peak virus titer of 0.9–1.4 × 107 PFU/mL at 36–48 hpi, and
produced foci of 5.9 mm diameter.
We further analyzed the replicative and cytopathic potential of the three cDNA-derived ZIKVs
in 16 other animal cell lines from 11 different species, over the first 4 days after infection of the cells
with each virus at an MOI of 1. Our data revealed seven distinct patterns of viral growth kinetics
and cytopathogenesis, depending on a combination of the viral strain and host cell line (Figure 3D
and Figure S3): (1) In all three human cell types (embryonic kidney HEK, hepatocarcinoma Huh-7,
and neuroblastoma SH-SY5Y), rMR-766 and rP6-740 grew equally well, to maximum titers of 107–108
PFU/mL at 48–72 hpi, but rPRVABC-59 always grew at a slower rate, attaining a peak titer 1–2 logs
lower than that of the other two strains at 72–96 hpi (HEK and SH-SY5Y) or reaching a peak titer
similar to that of the other two strains only at 96 hpi (Huh-7); all three ZIKVs induced cell death, with a
correlation between the degree of CPE and the magnitude of viral replication. (2) In swine testis (ST)
and equine skin (NBL-6) cells, the three ZIKVs replicated to their peak titers of 106–107 PFU/mL at
48 hpi, with differential growth rates similar to those seen in Vero cells (rMR-766, fastest; rP6-740,
slowest; rPRVABC-59, intermediate) that paralleled the kinetics of CPE development. (3) In sheep fetal
fibroblast (SFF-6) and A. albopictus (C6/36) cells, the three ZIKVs shared a superimposable growth
curve, characterized by a steady increase in virus titers up to ~107 PFU/mL by 96 hpi, except for rP6-740,
which had an exponential growth during 24–48 hpi in C6/36, but not SFF-6 cells. None of the three
ZIKVs produced any visible CPE. (4) In goat fetal fibroblast (GFF-4), canine kidney (MDCK), and feline
kidney (CRFK) cells and in all three mouse cell types (C57BL/6-derived embryonic fibroblast MEF,
NIH/Swiss-derived embryonic fibroblast NIH/3T3, and motor neuron-like hybrid NSC-34), rMR-766
was the fastest-growing, reaching its highest titer of 106–107 PFU/mL at 48–96 hpi; rPRVABC-59 was
the slowest-growing, gaining a maximum titer of only 103–104 PFU/mL during the same period;
and rP6-740 was intermediate in growth rate. However, none of these viruses produced visible CPE.
(5) In chicken embryo fibroblast (CEF) cells, both rMR-766 and rP6-740 had a relatively long lag period
of 36 h, followed by a gradual increase in virus titer up to 105–106 PFU/mL by 96 hpi; in contrast,
rPRVABC-59 grew extremely poorly, resulting in a slow decrease in virus titer to 45 PFU/mL by
96 hpi. No CPE was observed for any of the three ZIKV-infected CEF cells. (6) In bovine turbinate (BT)
cells, the three ZIKVs showed substantial differences in growth kinetics, reaching a plateau at 96 hpi,
with peak titers of 4.4 × 105 (rMR-766), 5.0 × 104 (rPRVABC-59), and 8.8 × 102 (rP6-740) PFU/mL.
However, no visible CPE was induced in any of the ZIKV-infected cells. (7) In bovine kidney (MDBK)
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cells, the titers of all three ZIKVs declined to undetectable levels at 60–96 hpi, with no overt signs of
viral replication.
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Figure 3. ZIKV replication kinetics and cytopathogenicity in cell cultures depend on the particular
combination of virus strain and host cells. (A–C) Replicative and cytopathic properties of three
cloned cDNA-derived ZIKVs (rMR-766, rP6-740, and rPRVABC-59) and their uncloned parental ZIKVs
(MR-766, P6-740, and PRVABC-59) in Vero cells. Cells were infected with each of the six ZIKVs (MOI = 1).
At the time points indicated after infection, cells were lysed to examine th accumulation levels of
viral genomic RNA by rea -time RT-PCR with a ZIKV-sp cific fluorogenic probe (A), and upernatants
were collected to analyze the roduction levels of progeny virions by plaque assays on Vero cells
(B). At 5 days post-infection, cell monolayers maintained under a semisolid overlay medium were
immunostained with rabbit α-ZNS1 antiserum to visualize the infectious foci (C). (D) Growth kinetics
and cytopathogenicity of the three cloned cDNA-derived ZIKVs in a wide range of animal cells (see
also Figure S3). Each virus was used to infect the cell lines (MOI = 1) specified in the figure. At the
indicated time points, cells were examined microscopically for the degree of ZIKV-induced cytopathic
effect (CPE) (–, 0%; +, 0–25%; ++, 25–50%; +++, 50–75%; ++++, 75–100% cell death), and supernatants
were assayed for virus production by plaque assays on Vero cells. hpi, hours post-infection.
Subsequently, we showed that MDBK cells are not susceptible to ZIKV infection, but instead are
permissive for ZIKV RNA replication, by using (i) single cell-based immunofluorescence (Figure 4A)
and flow cytometry (Figure 4B) assays to determine the number of cells expressing ZIKV proteins
(E or NS4 ), when MDBK cells wer either infected with e ch of the three cDNA-derived ZIKVs
or transfected with each of the three infectious RNAs transcribed in vitro from their corresponding
cDNAs; and (ii) total cell lysate-based immunoblot analyses to assess the accumulation levels of ZIKV
NS1 protein in the virus-infected vs RNA-transfected MDBK cells (Figure 4C). In all these experiments,
we used Vero cells, a ZIKV-susceptible cell line, as a control. Our results led us to postulate that MDBK
cells might lack one or more host factors required for ZIKV entry; alternatively, they might have a
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general defect in the clathrin-dependent endocytic pathway that ZIKV utilizes for internalization [63].
We thus investigated the functional integrity of the clathrin-dependent endocytic pathway in MDBK
cells, by analyzing the susceptibility of these cells to infection by two other enveloped RNA viruses
whose entry depends on clathrin-mediated endocytosis: bovine viral diarrhea virus (BVDV) and
vesicular stomatitis virus (VSV). In contrast to their resistance to ZIKV infection, we found that MDBK
cells were highly susceptible to infection with both BVDV and VSV, as demonstrated by their plaque
formation and high level of progeny virion production (Figure S4A,B). These results indicate that the
cellular machinery associated with the clathrin-dependent endocytic pathway is functional in MDBK
cells, and they support our hypothesis that MDBK cells lack a host factor(s) promoting ZIKV entry.
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Figure 4. MDBK cells are permissive for ZIKV RNA replication but are not susceptible to infection
with the virus. DBK cells were mock-inf cted or infected with rMR-766, rP6-740, or rPRVABC-59 at
an MOI of 3 (for virus infection experiments), or mock-transfected or transfected with 3 µg of synthetic
RNAs transcribed in vitro from their respective infectious cDNAs (for RNA transfection experiments).
At the indicated time points, the expression of three ZIKV proteins (E, NS1, and NS4A) within the cells
was analyzed by co focal microscopy for E (A), flow cytometry for NS4A (B), and immunoblotting
for NS1 (C). The insets in panel A show enlarged views of the boxed areas with the fluorescence of
propidium iodide (PI)-st ined nucl i excluded. In all exp riments, ZIKV-sus ptibl Vero cells were
included in par llel. hpi, hours post-infection; hpt, hours post-transfection.
3.4. Genome-Wide Landscape of the Viral Gene Products and Their Related Species Produced by the Molecularly
Cloned ZIKVs
To identify all the viral proteins produced by rMR-766, rP6-740, and rPRVABC-59, we examined
total cell lysates of mock- and ZIKV-infected Vero cells in two series of immunoblotting experiments.
In the first series, we probed with each of our 15 JEV region-specific rabbit antisera (Figure S5),
originally produced to detect all JEV gene products [31], which we estimated to have the potential for
cross-reactivity with their ZIKV counterparts, given the relatively high levels (35–71%) of amino acid
sequence identity between their antigenic regions (Figure 5A). Indeed, six (α-JEN-term, α-JNS1C-term,
α-JNS2B, α-JNS3C-term, α-JNS5N-term, and α-JNS5C-term) of the 15 antisera showed moderate-to-strong
cross-reactivity with their respective ZIKV gene products, but the remaining nine had no reactivity
(Figure 5B). To cover the remaining undetected parts of ZIKV ORF, we then generated seven ZIKV
region-specific rabbit antisera, using rPRVABC-59 as the viral strain of choice, immunizing the rabbits
with five bacterially expressed GST fusion proteins (α-ZC, α-ZM, α-ZE, α-ZNS4A, and α-ZNS4B) or
two chemically synthesized oligopeptides (α-ZNS1 and α-ZNS2B) (Figure S6A,B). In all cases, the 19
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to 51 aa antigenic regions of ZIKV were selected to have relatively low levels (16–42%) of amino acid
sequence identity with those of JEV (Figure 6A). The resulting seven ZIKV region-specific antisera were
used for a second series of immunoblots, in which we detected their respective ZIKV gene products
(Figure 6B). In all immunoblots, we included two additional cell lysates (as a reference for JEV proteins)
extracted from Vero cells infected with the virulent JEV strain SA14 or its attenuated strain SA14-14-2;
both JEVs share the same genome-wide viral protein expression profile, except that the NS1′ protein is
expressed only by SA14 [57].
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Figure 5. A subset of 15 JEV region-specific polyclonal antibodies detects the cross-reactive ZIKV E, NS1,
NS2B, NS3, NS5, and their related sp cies in ZIKV-inf cted c lls. (A) Schematic illustration showing
the antigenic regions recognized by 15 JEV region-specific rabbit antisera. The 10,977 nt genomic RNA
of JEV SA14 has a 95 nt 5′NCR, a 10,299 nt ORF, and a 583 nt 3′NCR (top panel). The ORF encodes a
3432 aa polyprotein that is processed by viral and cellular proteases into at least 10 mature proteins
(middle panel). Marked on the polyprotein are one or two transmembrane domains (vertical black bar)
at the C-termini of three structural proteins (C, prM, and E) and at the junction of NS4A/NS4B, as well
as four N-glycosylation sit s (as erisk) in the pr p rtion of prM (15NNT), E (154NYS), and NS1 (130NST
and 207NDT). During viral morphogenesis, prM is cleaved by furin protease into a soluble pr peptide
and a virion-associated M protein. NS1′ is the product of a −1 ribosomal frameshift (F/S) event that
occurs at codons 8–9 of NS2A, adding a 52 aa C-terminal extension to the NS1 protei . The bottom
panel displays the antigenic regions (horizontal blue bar) recognized by 15 JEV region-specific rabbit
antisera. (B) Identification of viral proteins in ZIKV-infected cells by immunoblotting. Vero cells were
mock-infected or infected at MOI 1 with each of three ZIKVs (rMR-766, rP6-740, and rPRVABC-59) or
two JEVs (SA14 and SA14-14-2, for reference). At 20 h post-infection, total cell lysates were separated
by SDS-PAGE on a glycine (Gly) or tricine (Tri) gel and analyzed by immunoblotting with each of the
15 JEV region-specific rabbit antisera or α-GAPDH rabbit antiserum as a loading and transfer control.
Molecular size markers are given on the left of each blot, and major JEV proteins for reference are
labeled on the right. Provided below each blot are the estimated molecular sizes of the predicted ZIKV
proteins, and marked on the blot are the predicted proteins (yellow or pink dot) and presumed cleavage
intermediates or further cleavage/degradation products (white circle). CHO, N-glycosylation.
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Figure 6. A panel of seven ZIKV region-specific polyclonal antibodies identifies ZIKV C, prM/M, E,
NS1, NS2B, NS4A’, NS4B, and their related species in ZIKV-infected cells. (A) Schematic illustration
showing th antigenic regions recognized by even ZIKV region-specific rabbit antisera. The 10,807 nt
genomic RNA of ZIKV PRVABC-59 consists of a 107 nt 5′NCR, a 10,272 nt ORF, and a 428 nt 3′NCR
(top panel). The ORF encodes a 3423 aa polyprotein that is predicted to be cleaved by viral and cellular
proteases into at least 10 mature proteins (middle panel). Marked on the polyprotein and its products
are one or two transmembrane domains (vertical black bar) at the C-termini of three structural proteins
(C, prM, and E) and at the junction of NS4A/NS4B, as well as four N-glycosylation sites (asterisk)
in the pr portion of prM (70NTT), E (154NDT), and NS1 (130NNS and 207NDT). The bottom panel
shows the antig nic regions (h izontal magenta bar) r cognized by seven ZIKV region-specific rabbit
antisera. (B) Identification of viral proteins in ZIKV-infected cells by immunoblotting. Vero cells were
mock-infected or infected at MOI 1 with each of three ZIKVs (rMR-766, rP6-740, and rPRVABC-59)
or two JEVs (SA14 and SA14-14-2, for comparison). At 20 h post-infection, total cell lysates were
separated by SDS-PAGE on a glycine (Gly) or tricine (Tri) gel and analyzed by immunoblotting with
each of the seven ZIKV region-specific rabbit antise a or α-GAPDH rabbit antiserum a a loading and
transfer control. Molecular size markers ar given on the left of each blot, nd major ZIKV proteins are
labeled on the right. Provided below each blot are the estimated molecular sizes of predicted ZIKV
proteins, and marked on the blot are the predicted proteins (yellow or pink dot) and presumed cleavage
intermediates or further cleavage/degradation products (white circle). CHO, N-glycosylation.
Our immunoblot analysis using a collection of 13 ZIKV antigen-reactive region-specific rabbit
antisera allowed us to create a full catalog of viral gene products and their related species, except
for the predicted 24 kDa NS2A (Figures 5 and 6): (1) α-ZC recognized the 13 kDa C protein, with no
accumulation of the further-processed 12 kDa C’ (see below for description of virion-associated
proteins), but with appearance of one or two cleavage products of 10–11 kDa in rPRVABC-59- or
rP6-740-infected cells, respectively; however, this antiserum did not react with any of the C-related
proteins of rMR-766. (2) α-ZM reacted strongly with the 9 kDa M protein and its 24 kDa precursor
prM, with the ratio of M:prM varying in the presence of equal amounts of the loading control GAPDH
protein, depending on the viral strain; the observed size of prM was 5 kDa larger than its predicted
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size, consistent with an addition of N-glycans at Asn-70 (70NTT) to its pr domain [64] that is conserved
in all three ZIKVs. Also, the α-ZM reacted weakly with at least two minor proteins of 15 and 19
kDa. (3) α-JEN-term/α-ZE detected four E-related proteins (of 54/56, 43/45, 24/26, and 14 kDa).
Among these, the first three proteins from rP6-740 were all 2 kDa smaller than those from rMR-766
and rPRVABC-59, in agreement with a missense mutation of the N-glycosylation site at Asn-154
(154NDT→NDI) in the E protein of rP6-740 relative to that of rMR-766 and rPRVABC-59 [19,20]. Indeed,
the three 2 kDa smaller proteins from rP6-740 became similar in size to those from rMR-766 and
rPRVABC-59, when the mutated N-glycosylation motif in rP6-740 was restored by changing 154NDI
into 154NDT, but not by changing 154NDI into 154QDT (Figure S7A–C). (4) Both α-JNS1C-term and
α-ZNS1 identified the 45 kDa NS1 exclusively. This protein was 5 kDa larger than predicted by its
amino acid sequence because of the addition of N-glycans at Asn-130 (130NNS) and Asn-207 (207NDT),
both of which are conserved in all three ZIKVs [65,66]. As expected, these data also showed that only
NS1, and not its frameshift product NS1’, was produced by all three ZIKVs. (5) α-JNS2B/α-ZNS2B
revealed the 14 kDa NS2B, together with a minor protein of 11 kDa at a barely detectable level.
(6) α-JNS3C-term recognized the 69 kDa NS3; it also reacted more strongly with a major cleavage
product of 34 kDa, representing the C-terminal half of the full-length NS3 [31], and less intensely
with at least seven minor proteins of 33–60 kDa. Intriguingly, α-JNS3C-term detected a species with
a mass of 85 kDa, corresponding to the calculated size of an NS2B-3 or NS3-4A/4A’ processing
intermediate. (7) α-ZNS4A did not detect the predicted 16 kDa NS4A, but did predominantly recognize
its further-processed 14 kDa NS4A’, which ran as a single species in tricine–SDS-PAGE but migrated as
a doublet in glycine–SDS-PAGE. Unexpectedly, this antiserum also identified two clusters of multiple
protein bands, one at 29 kDa (NS4Ap29) and the other at 35 kDa (NS4ABp35, which also reacted with
α-ZNS4B; Figure S8A,B). (8) α-ZNS4B stained the predicted major 27 kDa NS4B, along with two minor
proteins at 11 kDa (NS4Bp11) and 35 kDa (NS4ABp35, which again reacted with α-ZNS4A; Figures
S8A,B). (9) α-JNS5N-term and α-JNS5C-term reacted with the predicted 103 kDa NS5.
In addition to the three full-length structural proteins (C, prM/M, and E) of ZIKV, their multiple
smaller products were accumulated to lower but still significant amounts in Vero cells infected with
each of the three ZIKVs, with nearly the same protein expression profile (Figure 6). To define the
actual viral structural proteins incorporated into ZIKV particles, rPRVABC-59 was used to profile
all the structural proteins associated with extracellular virions, which were purified by pelleting
through a 20% sucrose cushion. We then compared them with their cell-associated counterparts by
immunoblotting with α-ZC, α-ZM, and α-ZE (Figure 7). The purified ZIKV particles were shown
to contain (i) the 12 kDa C’ protein, which appeared as a closely spaced doublet with the lower
band being more prominent than the upper band and migrating in a gel marginally faster than
one cell-associated major 13 kDa C protein, but slower than the other cell-associated minor 10 kDa
C-derived cleavage product; (ii) the 9 kDa M protein and a trace amount of its glycosylated precursor
prM, which appeared as two bands, the slightly less intense and faster one migrating with a mass of
23–24 kDa and the slightly more intense and slower one at 25–26 kDa, reflecting the trimming of high
mannose and the addition of more complex sugars to the cell-associated 24 kDa prM protein during
virus release through the cellular secretory pathway [67]; and (iii) the glycosylated 58 kDa E protein,
which ran slightly slower than the cell-associated 56 kDa E protein, again reflecting the difference in its
glycosylation status. Collectively, we have demonstrated that the extracellular ZIKVs are composed of
three post-translationally modified full-length structural proteins, excluding their smaller species.
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weight markers are shown on the left of each blot. The molecular weights of predicted C, C’, prM, M,
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3.5. Wide Range of Differences in Age-Dependent Neuropathogenicity among Three Molecularly Cloned ZIKVs
in Outbred CD-1 Mice
We compared the virulence of rMR-766, rP6-740, and rPRVABC-59 in CD-1 mice at three different
ages (1, 2, and 4 weeks) by examining two neuropathogenic properties: (i) neuroinvasiveness
(the ability to penetrate the central n rvous s st m from a peripheral site), quantified by g nerating
th dose-dep dent survival curve and d termini g the LD50 after an im inoculation; and (ii)
neurovirulence (the ability to establish a lethal infection within the central nervous system), quantified
by creating the dose-dependent survival curve and measuring t e LD50 fter an ic inoculation. For both
im and ic inoculations, we first determi ed the appropriate dose ranges for calculating the LD50 values,
and we optimized the study designs prior to the performance of full-scale experiments. For these
pilot xperiments, we injected all three age groups of the mice with a maximum dose of ach virus:
1.2 × 105 PFU/mouse for im inoculations and 3.6 × 104 PFU/mouse for ic inoculati ns. If nec ssary,
e then perfor e a seri s of large-scale dose-resp nse studies, inoculating groups of the mice at
1, 2, and 4 weeks of age via the im or ic route with serial 10-fold dilutions of th virus. Following
infe tion, the mice were monitored daily for mortality, weight loss, and othe clinical signs of illness
over 20 days.
The comparative a sessments of our dose-dependent survival curves and LD50 values revealed the
following (Figure 8A): (i) rMR-766 exhibited ag - t neuroinvasiveness, as evidenced by an im
LD50 of 90.2 PFU for 1-week-old mice and >1.2 × 105 PFU for 2- a d 4-week-old mice, yet it isplayed
a high level neurovirulence at all three ag s, as evidenced by an ic LD50 of <3.6, 3.6, and 5.7 PFU
for 1-, 2-, and 4-we k-old mice, respectively. (ii) rP6-740 how d barely detectable neuroinvasiveness
in 1-week-old mice, with only 1 or 3 of 10 infect d mice d ing when inoculated with the two highest
doses, 3.6 × 103 or 3.6 × 104 PFU/mouse, respectively (im LD50, >3.6 × 104 PFU). Similarly, it had
no de ectable neuroinvasiveness in 2- and 4-week-old ice, with no inf cted mice dying even when
inoculated with the high s dose, 1.2 × 105 PFU/mouse (im LD50, >1.2 × 105 PFU). Howev r, rP6-740
showed age-dependent neurovirulence, as it was highly neurovirulent in 1-week-old mice (ic LD50,
<3.6 PFU) but non-neurovirulent in 2- and 4-week-old mice (ic LD50, >3.6 × 104 PFU). (iii) rPRVABC-59
was essentially non-neuroinvasive and non-neurovirulent, regardless of the mouse age, with its im and
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ic LD50 values estimated to be greater than the highest dose used for each route of infection, without
a single death. Of the three ZIKVs, therefore, rMR-766 was the most virulent, rPRVABC-59 was the
least virulent, and rP6-740 showed intermediate virulence. The observed differences in virulence are
correlated with the variations in viral passage history in mice (Figure 1A).
Moreover, we recognized not only the lethal virulence displayed by rMR-766 and rP6-740 but also
the non-lethal virulence exhibited by all of the three ZIKVs, including rPRVABC-59. This effect was
most prominent in 1-week-old mice (Figure 8B). The lethal virulence was invariably associated with a
sharp drop in the body weight of infected mice that began ~3 days prior to death, in conjunction with
clinical signs. It began with decreased activity, ruffled fur, and hunched posture, and often progressed
to tremors and hind limb paralysis. Various viral loads were detected postmortem in the brains of all
mice that died (8.0 × 103–3.9 × 108 PFU/brain). Non-lethal virulence, in contrast, was characterized
by an initial weight loss of various degrees, albeit without obvious clinical signs, and a subsequent
recovery, to some extent, that was not complete. At the end of the study, no infectious ZIKV was
detected in the brains of any of the mice that survived. In both the lethal and non-lethal virulent cases,
no changes in body temperature were observed. Altogether, we found that in CD-1 mice, the three
ZIKVs had a wide range of virulence, depending on the virus strain, mouse age, and route of infection.
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Figure 8. Three molecularly cloned ZIKVs display a full range of variation in neuropathogenicity
for outbred CD-1 mice in an age-dependent manner. Groups of CD-1 mice (n = 8–10, half male,
half female) w mock-inoculated or noculat d at 1, 2, and 4 weeks of ag via the intramuscular (im)
or intracerebral (ic) route with a maximum dose of 3.6× 104 or 1.2× 105 PFU, or serial 10-fold dilutions
of rMR-766, rP6-740, or rPRVABC-59. (A) Survival curves were generated by the Kaplan–Meier method,
and LD50 values were determined by the Reed–Muench method and are presented in the bottom left
corner of each curve. (B) Weight changes are plotted, with each mouse represented by one color-coded
line. dpi, days post-infection.
3.6. High Degree of Variation in Interferon (IFN) Sensitivity among Three Molecularly Cloned ZIKVs in Mice
Lacking Type I (IFNAR−/−) or Both Type I and II IFN (IFNAR−/−/IFNGR−/−) Receptors
To compare the contributions of the host IFN response to the virulence of rMR-766, rP6-740,
and rPRVABC-59, we examined their neuroinvasiveness and neurovirulence by using groups
of 4-week-old A129 (IFNAR−/−) mice and groups of age-matched wild-type inbred C57BL/6J
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mice as a control (Figure 9A). In the control mice, rMR-766 was non-neuroinvasive (im LD50,
>1.2 × 105 PFU) but neurovirulent (ic LD50, 7.8 PFU). In contrast, both rP6-740 and rPRVABC-59
were non-neuroinvasive (im LD50, >1.2 × 105 PFU) as well as non-neurovirulent (ic LD50, >3.6 × 104
PFU), in agreement with the data obtained in age-matched outbred CD-1 mice (Figure 8A). In A129
mice, however, the neurovirulence of all three ZIKVs was increased sharply, and they became
highly neurovirulent (ic LD50, <3.6 PFU), with median survival times estimated to be 4 (rMR-766),
5 (rP6-740), and 7 (rPRVABC-59) days, with a lethal dose of 3.6 × 102 PFU/mouse. Similarly,
the neuroinvasiveness of the three ZIKVs was also elevated but to different degrees, as evidenced
by the estimated im LD50 of <1.2 (rMR-766), 576.1 (rP6-740), and >1.2 × 105 (rPRVABC-59) PFU.
Noticeably, rPRVABC-59 was nearly non-neuroinvasive in A129 mice. This finding prompted us
to further test the neuroinvasiveness of rPRVABC-59, as compared to that of the other two ZIKVs,
in 4-week-old AG129 (IFNAR−/−/IFNGR−/−) mice (Figure 9A). In AG129 mice, all three ZIKVs
were highly neuroinvasive (im LD50, <1.2 PFU), although the median survival times for the three
viruses varied from 7 (rMR-766) to 12 (rP6-740) and 13 (rPRVABC-59) days, with a lethal dose of
1.2 × 102 PFU/mouse. Furthermore, in all three mouse strains (C57BL/6J, A129, and AG129), the two
LD50-based neuropathogenic properties of the three ZIKVs were always corroborated by the decreases
in body weight (Figure 9B), accompanied by the typical clinical signs seen in CD-1 mice. In all the
mice that died, various viral loads were detected in their brains postmortem, with higher loads
being found in the absence of IFN signaling, i.e., 4.7 × 104–2.0 × 108 PFU/brain for C57BL/6J,
1.3 × 106–1.0 × 109 PFU/brain for A129, and 8.5 × 106–3.6 × 109 PFU/brain for AG129. In the case of
all mice that survived, however, we detected no infectious ZIKV in the brain at the end of the study.
Taken together, these data show a full range of variation in IFN sensitivity among the three cloned
ZIKVs in mice.
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Figure 9. Three molecularly cloned ZIKVs show a full spectrum of variation in IFN sensitivity in mice
lacking type I or both type I and II IFN receptors. Groups of 4-week-old C57BL/6J (n = 8), A129 (n = 5),
or AG129 (n = 5) mice, approximately half of each sex, were mock-inoculated or inoculated through
the intramuscular (im) or intracerebral (ic) route with a maximum dose of 3.6 × 104 or 1.2 × 105 PFU,
or serial 10-fold dilutions of rMR-766, rP6-740, or rPRVABC-59. (A) Survival curves were created by the
Kaplan–Meier method, and LD50 values were calculated by the Reed–Muench method and are given
in the bottom left corner of each curve; (B) Weight changes are plotted, with each mouse indicated by
one color-coded line. NT, not tested; dpi, days post-infection.
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4. Discussion
Here, we report the first development of three full-length infectious ZIKV cDNAs as BACs for
each of three spatiotemporally distinct and genetically divergent ZIKV strains [54]: MR-766 (Uganda,
1947), P6-740 (Malaysia, 1966), and PRVABC-59 (Puerto Rico, 2015). We have also produced 13 ZIKV
region-specific polyclonal rabbit antisera capable of identifying all the viral structural and nonstructural
proteins and their related species, except for NS2A. Using our functional cDNAs and antibodies in
combination with various cell culture and murine model systems, we have demonstrated that the
three molecularly cloned cDNA-derived ZIKVs have the nearly same genome-wide viral protein
expression profile but differ in their replication kinetics and neuropathogenicity (neuroinvasiveness
and neurovirulence), depending on the particular combination of viral and host genetic backgrounds,
as well as in the presence or absence of type I/II IFN signaling. In particular, our results demonstrate
that type I IFN regulates ZIKV neuroinvasiveness in a virus strain-dependent manner. In all, these
reagents offer a new toolbox for viral genome engineering and protein analysis. Together with a roster
of in vitro and in vivo infection models, these tools will not only provide an ideal platform for defining
the viral and host genetic factors that contribute to ZIKV replication and pathogenesis at the cellular
and organismic levels, but also offer promising new avenues for developing and testing an effective,
critically needed vaccine against ZIKV.
The advent of functional cDNA-based reverse genetics has revamped the field of RNA viruses [68].
For flaviviruses, however, the cloned cDNAs are commonly unstable because of the toxicity of their
prM-E genes in host cells, posing a major technical challenge to functional cDNA construction [69].
In the present study, we cloned a complete cDNA copy of the ZIKV genomic RNA into a BAC vector
that is capable of stably housing a DNA fragment of >300 kb in bacteria [70], as we have already
done for JEV [53,58]. In the case of all three ZIKVs (MR-766, P6-740, and PRVABC-59), we showed
that the structural and functional integrity of their full-length BACs remained stable for at least 80
generations of growth in E. coli. To date, the BAC cloning technology has been applied to constructing
full-length infectious cDNAs for ~10 members of three plus-strand RNA virus families (Flaviviridae,
Arteriviridae, and Coronaviridae), all of which have a large genome size of 11–31 kb [52]. Moreover, we
performed site-directed mutagenesis to introduce a point mutation(s) into the full-length infectious
cDNA BAC clone of ZIKV P6-740, which demonstrated (i) the functional importance of His-713 within
the conserved structural motif E region in the RNA-dependent RNA polymerase domain of ZIKV NS5
for viral RNA replication and (ii) the functional significance of the N-glycosylation site at Asn-154 in
the viral E protein for its biogenesis. These results indicate that targeted mutations can be engineered
by manipulating the infectious ZIKV BACs in E. coli. Thus, our BAC-based reverse genetics for ZIKV
will facilitate genetic studies of both viral RNA elements and gene products associated with all aspects
of ZIKV biology.
We formulated a strategy to assemble three full-length infectious ZIKV cDNAs, each capable of
generating m7G-capped in vitro-transcribed RNAs identical in nucleotide sequence to their respective
genomic RNAs, particularly regarding the 5′- and 3′-end sequences. On the 5′ side, we positioned an
SP6 promoter sequence (5′-ATTTAGGGGACACTATAG, with transcription starting at the underlined
G) upstream of the first adenine nucleotide of the viral genome to incorporate the dinucleotide cap
analog m7GpppA in SP6 RNA polymerase-driven in vitro transcription reactions. The importance
of an m7G cap at the 5′-end of transcribed RNAs in maximizing RNA infectivity was shown by our
finding that uncapped RNAs derived from each of the three functional ZIKV cDNAs always had
an infectivity >3-logs lower than that of their m7G-capped counterparts. On the 3′ side, we placed
a unique restriction endonuclease recognition site, PsrI [(N7↓N12)GAACN6TAC(N12↓N7)] or BarI
[(N7↓N12)GAAGN6TAC(N12↓N7)], downstream of the last thymine nucleotide of the viral genome.
The use of PsrI/BarI for cDNA linearization is particularly advantageous because both are extremely
rare-cutting endonucleases that cut out their recognition sequences after any nucleotide, which makes
this approach applicable for all plus-strand RNA viruses, regardless of the identity of the nucleotide at
the 3′ end of the viral genome. We found that RNA transcripts with 11 ZIKV-unrelated nucleotides
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hanging on their 3′ ends were ~1-log less infectious than those with authentic 3′ ends, indicating the
importance of the authentic 3′ end for the production of infectious ZIKV RNAs.
Several functional cDNAs for ZIKV have hitherto been made using two different strategies,
depending on the vector adopted to clone its full-length cDNA and the method applied to create
the viral 5′ and 3′ ends: (i) The low-copy plasmid pACYC177 (~15 copies/cell) has been utilized to
house a complete cDNA flanked by a 5′ bacteriophage T7 promoter and a 3′ hepatitis delta virus
ribozyme (HDVr). This T7-HDVr system, analogous to our SP6-PsrI/BarI system, requires an in vitro
transcription and transfection of transcribed RNAs into cells for virus recovery. This “RNA-initiated”
approach has been implemented to clone the viral genomic RNA of the 2010 Cambodian FSS13025
strain [71]. To circumvent the need for a single plasmid containing a full-length cDNA, in vitro
ligation of two or four cDNA fragments pre-cloned individually into the low-copy pACYC177 or
high-copy pUC57 (500–700 copies/cell) plasmid, although relatively inefficient, has been done to
generate a full-length cDNA template prior to in vitro transcription using the T7-HDVr system for
the Ugandan MR-766 (1947), French Polynesian H/PF/2013 (2013), Puerto Rican PRVABC-59 (2015),
and Brazilian SPH2015 (2015) and BeH819015 (2015) strains [49,72]. (ii) The low-copy pACNR1811
(10–20 copies/cell) or high-copy pcDNA6.2 (500–700 copies/cell) plasmid is used to house a full-length
cDNA containing one or two artificial introns to restrict its instability during propagation in E. coli. In
this case, a eukaryotic RNA polymerase (RNAP) II-dependent cytomegalovirus (CMV) promoter is
positioned before the viral 5′ end, and a pair of HDVr and an SV40 poly(A) signal/RNAP II terminator
are placed after the viral 3′ end. Unlike our SP6-PsrI/BarI system, the CMV-HDVr system requires
transfection of cells with a plasmid carrying the intron-bearing full-length cDNA. This “DNA-initiated”
approach has been applied to clone the viral genomic RNA of the Ugandan MR-766 (1947) and Brazilian
Paraiba (2015) strains [73,74]. Alternatively, a circular form of the intronless full-length cDNA for
the 2015 Brazilian Natal strain has been generated by PCR-mediated joining of eight overlapping
cDNA fragments that are pre-cloned individually into the high-copy pUC plasmid [75]. Although far
less efficient, a similar PCR-based method has also been reported that uses three overlapping cDNA
fragments covering the viral genomic RNA with no joining of these fragments into a circular cDNA [76].
In the present study, we developed a single plasmid-based RNA-initiated reverse genetics system for
ZIKV that not only maximizes the genetic stability of its cloned cDNA using a single-copy BAC as a
vector, but also optimizes the synthesis of infectious RNAs in vitro using the SP6-PsrI/BarI system.
ZIKV circulates in a sylvatic cycle between nonhuman primates (NHPs) and forest-dwelling
mosquitoes, as well as in an urban cycle between humans and town-dwelling mosquitoes [12]. Apart
from NHPs, however, information is scarce on any potential animal hosts or reservoirs for ZIKV
transmission. Using our three cDNA-derived genetically distinct ZIKVs, we evaluated their ability to
infect and replicate in 17 animal cell lines from 12 different species (monkeys, humans, mosquitoes,
mice, cows, pigs, sheep, goats, horses, dogs, cats, and chickens). Our data showed that ZIKV has a
broad cell tropism in vitro, being capable of establishing productive infection in 16 of the 17 cell lines
we tested, although its growth rate and ability to induce CPE varied widely depending on both the
specific virus strain and host cell line. Of particular note, all three ZIKVs grew readily in both porcine
ST and equine NBL-6 cells, with their growth kinetics similar to those observed in simian Vero cells;
generally, they also replicated and spread equally well in ovine SFF-6 cells and in aedine C6/36 cells.
These results raise a question as to whether several agriculturally important domestic animals (e.g.,
pigs, sheep, and horses) are susceptible to ZIKV infection, particularly when young. With respect
to this question, two recent studies have reported that fetal and neonatal piglets are susceptible to
experimental infection with ZIKV [77,78]. Another pilot study has suggested that a range of adult
animals, including rabbits, goats, pigs, cattle, chickens, and ducks, are less likely to act as animal
hosts for ZIKV, based on the levels of viremia and neutralizing antibody titer induced following ZIKV
infection; of these animals, however, rabbits and pigs are proposed to be able to serve as sentinels
for ZIKV surveillance [79]. Clearly, further investigation is needed to elucidate the susceptibility of
these animals to ZIKV infection, preferentially in the presence or absence of type I IFN signaling,
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and might provide new opportunities to increase our understanding of ZIKV biology and to develop
a non-murine model for ZIKV research. Moreover, we discovered a nonsusceptible bovine MDBK
cell line that has a block in ZIKV entry but fully supports the subsequent post-entry steps; however,
this cell line remained highly susceptible to infection by two other enveloped RNA viruses, BVDV [80]
and VSV [81], which like ZIKV [63], enter the cells through clathrin-dependent endocytic pathway.
This ZIKV-nonsusceptible bovine cell line thus offers a unique opportunity to identify the host factors
involved in ZIKV entry.
To our knowledge, this work is the first to generate such a large panel of 13 ZIKV region-specific
antibodies that can identify experimentally nearly all the viral gene products and their related species
in ZIKV-infected Vero cells and define all three structural proteins associated with extracellular
virions. Our data are in overall good agreement with the current model for flavivirus polyprotein
processing [21], but they have also revealed a considerable number of previously undescribed,
presumed cleavage intermediates or further cleavage/degradation products. The main findings from
our study are as follows: (1) While the full-length 13 kDa C and its one or two processed 10 to 11 kDa
proteins were accumulated intracellularly, the extracellular virion-associated C’ protein appeared as
a tightly spaced 12 kDa doublet. (2) For each of the two viral surface glycoproteins (24 kDa prM
and 54/56 kDa E), two or three smaller products were also cell-associated but not virion-associated.
(3) Only the 45 kDa NS1, and not its theoretically frameshift-derived product NS1’, was expressed. (4) In
addition to the intact 14 kDa NS2B, its processed 11 kDa product was also stained, although weakly.
(5) The full-length 69 kDa NS3 was processed to yield multiple truncated species of 33–60 kDa, of which
the C-terminal 34 kDa fragment was the most prominent species. (6) The predicted 16 kDa NS4A was
completely undetectable, but three unpredicted NS4A-related proteins were readily identified, i.e.,
a major doublet at 14 kDa (NS4A’) and two minor protein clusters at 29 kDa (NS4Ap29) and 35 kDa
(NS4ABp35). (7) Not only the predicted 27 kDa NS4B but also two unpredicted NS4B-related proteins
were observed, one at 11 kDa (NS4Bp11) and the other at 35 kDa (NS4ABp35). However, the functional
importance of the previously undescribed cleavage intermediates or further cleavage/degradation
products in ZIKV biology remains to be determined.
Much progress has been made over the past year in developing animal models (i.e., mice and
NHPs) for ZIKV [43]. To date, the mouse is the most feasible small animal that mimics aspects of
ZIKV infection in humans, albeit with some limitations resulting from species differences in innate
immunity, reproductive system, and fetal development. Previously, no productive infection was
detected when several strains of immunocompetent adult mice were inoculated peripherally with
diverse ZIKVs, but robust peripheral ZIKV infection causing substantial morbidity and mortality was
observed in both immunocompromised adult and immunocompetent neonatal mice [44,46,82–89].
We call attention, however, to the large variation in ZIKV pathogenicity among the previous studies,
which were conducted by inoculating a variety of ZIKVs into different strains of mice via various
routes. In the current report, we have shown in immunocompetent CD-1 mice at 1, 2, and 4 weeks
of age that ZIKV neuropathogenicity can only be defined in the context of a virus-host combination,
particularly depending on both viral strain and mouse age, as evidenced by comparison of the
neuroinvasiveness and neurovirulence of our three molecularly cloned, genetically distinct ZIKVs: (i)
rMR-766 exhibited neonate-specific age-dependent neuroinvasiveness but displayed a high level of
neurovirulence at all three ages. (ii) rP6-740 had little-to-no neuroinvasiveness at all three ages but
possessed neonate-specific age-dependent neurovirulence. (iii) rPRVABC-59 was non-neuroinvasive
and non-neurovirulent at all three ages. Also, we showed marked differences in IFN sensitivity among
the three ZIKVs: In 4-week-old A129 (IFNAR−/−) mice, the three ZIKVs were uniformly neurovirulent
but varied in neuroinvasiveness (rMR-766, neuroinvasive; rP6-740, intermediate; and rPRVABC-59,
almost non-neuroinvasive); however, all three ZIKVs, including rPRVABC-59, were neuroinvasive
in age-matched AG129 (IFNAR−/−/IFNGR−/−) mice. Consistent with previous work, we noted a
greater susceptibility and more severe disease in AG129 mice than in A129 mice [44–49]. In all fatal
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cases, the mortality was related to the productive infection in the brain, coupled with tremors, ataxia,
and hind limb paralysis.
In conclusion, use of our newly developed comparative functional genomics and immunologic
tools, combined with various cell culture and mouse infection model systems, will facilitate further
research leading to ZIKV disease prevention and therapy, as well as an in-depth understanding of
ZIKV biology.
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